- Home
- WGSWW vs REVG Comparison
WGSWW vs REVG Comparison
Compare WGSWW & REVG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WGSWW
- REVG
- Stock Information
- Founded
- WGSWW 2017
- REVG 2008
- Country
- WGSWW United States
- REVG United States
- Employees
- WGSWW 1000
- REVG N/A
- Industry
- WGSWW Retail: Computer Software & Peripheral Equipment
- REVG Auto Manufacturing
- Sector
- WGSWW Technology
- REVG Consumer Discretionary
- Exchange
- WGSWW Nasdaq
- REVG Nasdaq
- Market Cap
- WGSWW N/A
- REVG N/A
- IPO Year
- WGSWW N/A
- REVG 2017
- Fundamental
- Price
- WGSWW $0.05
- REVG $36.40
- Analyst Decision
- WGSWW
- REVG Hold
- Analyst Count
- WGSWW 0
- REVG 4
- Target Price
- WGSWW N/A
- REVG $33.75
- AVG Volume (30 Days)
- WGSWW 36.6K
- REVG 608.2K
- Earning Date
- WGSWW 02-18-2025
- REVG 06-04-2025
- Dividend Yield
- WGSWW N/A
- REVG 0.66%
- EPS Growth
- WGSWW N/A
- REVG N/A
- EPS
- WGSWW N/A
- REVG 1.77
- Revenue
- WGSWW $305,450,000.00
- REVG $2,319,300,000.00
- Revenue This Year
- WGSWW N/A
- REVG $1.97
- Revenue Next Year
- WGSWW N/A
- REVG $6.51
- P/E Ratio
- WGSWW N/A
- REVG $20.64
- Revenue Growth
- WGSWW 50.79
- REVG N/A
- 52 Week Low
- WGSWW $0.17
- REVG $21.54
- 52 Week High
- WGSWW $0.21
- REVG $36.06
- Technical
- Relative Strength Index (RSI)
- WGSWW N/A
- REVG 71.20
- Support Level
- WGSWW N/A
- REVG $31.57
- Resistance Level
- WGSWW N/A
- REVG $36.06
- Average True Range (ATR)
- WGSWW 0.00
- REVG 1.03
- MACD
- WGSWW 0.00
- REVG 0.47
- Stochastic Oscillator
- WGSWW 0.00
- REVG 98.18
About WGSWW GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.